A Phase 3 interventional study of Ruxolitinib and Placebo in Cytokine Storm (Covid-19), sponsored by Novartis Pharmaceuticals. Completed at 61 sites in 12 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2021-10-11.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 49 studies in Cytokine Release Syndrome with a site in United States — 11 open to participants now, 14 under way, 1 of them phase 3. Cytokine Release Syndrome · United States.
Among the 49 studies in Cytokine Release Syndrome with a site in United States, this one is the 3rd largest by enrollment of the 46 interventional ones that give a count, is one of 24 that started in 2020, is one of 7 in phase 3, and was the 14th registered.
163 studies on the registry are indexed under Cytokine Release Syndrome; 31 are open to participants now.
Browse Cytokine Release Syndrome studies →11 of the 49 studies in Cytokine Release Syndrome with a site in United States are open now. Recruiting first, the newest first:
Naresh Bumma · Sites in United States
Ages 18+
Regeneron Pharmaceuticals · Sites in United States
Ages 18+
University of Utah · Sites in United States
Ages 21+
Hoffmann-La Roche · Sites in United States, Australia, Canada and 4 more countries
Ages 18+
Taylor Brooks · Sites in United States
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 20 Cytokine Release Syndrome studies recruiting now, 15 (75%) set no upper age limit and 2 (10%) stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
49 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 27 · Phase 3 9 · Phase 4 2
First in 2012; this study’s year is marked. 24 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 432 is above the median of 48 across 117 interventional studies indexed under Cytokine Release Syndrome.
Median enrollment 29 across the 46 interventional studies, 210 across the 3 observational. Of the 25 that completed or were terminated, 16 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 49 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Novartis has 3 studies filed under Cytokine Release Syndrome — fewer than ten, so there is no comparison to draw.
3 of the studies in Cytokine Release Syndrome with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05905328CytoAgents, Inc.Study of CTO1681 for the Prevention and Treatment of CRS in Patients Receiving CAR T-Cell Therapy | 2027-06 |
| NCT05972135SCRI Development Innovations, LLCOutpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma | 2027-08 |
| NCT07609940Regeneron PharmaceuticalsAdult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS) | 2027-10-11 |
Add all 3 to your calendar (.ics) → With an account.
Among the 49 studies in Cytokine Release Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This was a randomized, double-blind, placebo-controlled, 29-day, multicenter study to assess the efficacy and safety of ruxolitinib + standard-of-care (SoC) therapy, compared with placebo + SoC therapy, in patients aged ≥12 years with COVID-19 disease.
This was a Phase III, multicenter, double-blind, randomized, placebo-controlled study to assess the efficacy and safety of ruxolitinib in patients aged ≥12 years with COVID-19 disease. The study enrolled patients to ruxolitinib or placebo, in addition to standard of care (SoC) per local practice. Patients who meet the inclusion/exclusion criteria were randomized in a 2:1 ratio to either oral ruxolitinib 5 mg twice daily + SoC or oral matching-image placebo + SoC for a total of 14 days. An additional 14 days of study drug could be given if in the opinion of the investigator the patient's clinical signs and symptoms did not improve, or worsen, and the potential benefit outweighed the potential risk.
The study included:
The primary objective was to evaluate the efficacy (as measured by a composite endpoint of proportion of patients who die, develop respiratory failure [require mechanical ventilation], or require intensive care unit care) of ruxolitinib + standard-of-care (SoC) therapy compared with placebo + SoC therapy, for the treatment of COVID-19 by Day 29.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patient or guardian/health proxy must provide (and assent if applicable) before any study assessment is performed.
Male and female patients aged ≥ 12 years (or ≥ the lower age limit allowed by Health Authority and/or Ethics Committee/Institutional Review Board approvals).
Patients with coronavirus (SARS-CoV-2) infection confirmed by polymerase chain reaction (PCR) test or another rapid test from the respiratory tract prior to randomization.
Patients currently hospitalized or will be hospitalized prior to randomization.
Patients, who meet at least one of the below criteria:
Exclusion Criteria:
History of to any drugs or metabolites of similar chemical classes as ruxolitinib.
Presence of severely impaired renal function defined by serum creatinine > 2 mg/dL (>176.8 μmol/L), or have estimated \< 30 ml/min measured or calculated by Cockroft Gault equation or calculated by the updated bedside Schwartz equation.
Suspected uncontrolled bacterial, fungal, viral, or other infection (besides COVID-19).
Currently intubated or intubated between screening and randomization. In intensive care unit (ICU) at time of randomization. Intubated or in ICU for COVID-19 disease prior to screening. Patients who are on anti-rejection, or immunomodulatory drugs (i.e. tocilizumab, ruxolitinib, canakinumab, sarilumab, anakinra).
Unable to ingest tablets at randomization. Pregnant or nursing (lactating) women
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ruxolitinib 5 mg tablets twice daily (b.i.d.) for 14 days with possible extension of treatment to 28 days
Drug: Ruxolitinib
Matching-image placebo for 14 days with possible extension of treatment to 28 days
Drug: Placebo
Ruxolitinib 5 mg tablets
Also known as: INC424
Matching-image placebo
Proportion of Patients Who Die, Develop Respiratory Failure [Require Mechanical Ventilation] or Require Intensive Care Unit (ICU) Care
Efficacy is measured by a composite endpoint of proportion of patients who die, develop respiratory failure \[require mechanical ventilation\], or require intensive care unit \[ICU\] care for the treatment of COVID-19. Analyses are cumulative, thus analysis on Day 29 includes all events till that day. Patients who developed respiratory failure and/or required ICU at randomization are excluded from the analysis.
Time frame: Day 1 - Day 29
Clinical Status
Clinical status is measured with the 9-point ordinal scale. The scoring is: * Uninfected patients have a score 0 (no clinical or virological evidence of infection). * Ambulatory patients (not in hospital or in hospital and ready for discharge) can have a score 1 (no limitation of activities) or 2 (limitation of activities). * Hospitalized patients with mild disease can have score 3 (no oxygen therapy defined as peripheral oxygen saturation (SpO2) ≥ 94% on room air) or 4 (oxygen by mask or nasal prongs). * Hospitalized patients with severe disease can have score 5 (non-invasive ventilation or high-flow oxygen), 6 (intubation and mechanical ventilation) or 7 (ventilation + additional organ support - pressors, RRT (renal replacement therapy), ECMO (extracorporeal membrane oxygenation)). * Patients who die have a score 8.
Time frame: Baseline, Day 15, Day 29
Percentage of Patients With at Least Two-point Improvement From Baseline in Clinical Status
Percentage of patients with at least two points improvement in clinical status on the 9-point ordinal scale. The baseline value of clinical status is defined as the last assessment prior to first dose of double-blind treatment. Patients with missing data at Day 15 and/or Day 29 are treated as non-responders.
Time frame: Baseline, Day 15, Day 29
Percentage of Patients With at Least One-point Improvement From Baseline in Clinical Status
Percentage of patients with at least one point improvement in clinical status on the 9-point ordinal scale. The baseline value of clinical status is defined as the last assessment prior to first dose of double-blind treatment. Patients with missing data at Day 15 and/or Day 29 are treated as non-responders.
Time frame: Baseline, Day 15, Day 29
Percentage of Patients With at Least One-point Deterioration From Baseline in Clinical Status
Percentage of patients with at least one point deterioration in clinical status on the 9-point ordinal scale. The baseline value of clinical status is defined as the last assessment prior to first dose of double-blind treatment. Patients with missing data at Day 15 and/or Day 29 are treated as non-responders.
Time frame: Baseline, Day 15, Day 29
Time to Improvement in Clinical Status
Time to improvement in clinical status from baseline category to one less severe category of the 9-point ordinal scale. The baseline value of clinical status is defined as the last assessment prior to first dose of double-blind treatment. Median time to improvement is estimated by Kaplan-Meier method, with dead patients being censored at the maximum follow-up time in the study. Patients who did not achieve improvement and did not die are censored at their last clinical status assessment date.
Time frame: 29 days
Mean Change From Baseline in the Clinical Status
Mean change from baseline in the 9-point ordinal scale. The baseline value of clinical status is defined as the last assessment prior to first dose of double-blind treatment. Patients with missing data at Day 15 and/or Day 29 are excluded from the analysis. A negative change from baseline in the clinical status is a favorable outcome.
Time frame: Baseline, Day 15, Day 29
Mortality Rate
Mortality rate is determined as the proportion of participants who died by study Day 15 and Day 29
Time frame: Day 15, Day 29
Proportion of Patients Requiring Mechanical Ventilation
Proportion of patients requiring mechanical ventilation. Analyses are cumulative, thus analysis on Day 29 includes all events till that day. Patients who required mechanical ventilation at randomization are excluded from the analysis.
Time frame: Day 1 - Day 29
Duration of Hospitalization
Duration of hospitalization is defined as time to hospital discharge. Median time to hospital discharge is estimated by Kaplan-Meier method, with dead patients being censored at the maximum follow-up time in the study. Patients who were not discharged and did not die are censored at their last assessment date.
Time frame: 29 days
Time to Hospital Discharge or to a NEWS2 Score of ≤2
The time to hospital discharge or to a National Early Warning Score 2 (NEWS2) of ≤2 and maintained for 24 hours whichever comes first. The NEWS2 is based on a simple aggregate scoring system in which a score is allocated to physiological measurements, already recorded in routine practice presentation or when a patient is being monitored in hospital. The score ranges from 0 (best) to 23 (worst). Median time is estimated by Kaplan-Meier method, with dead patients being censored at the maximum follow-up time in the study.
Time frame: 29 days
Change From Baseline in NEWS2 Score
The National Early Warning Score 2 (NEWS2) is based on a simple aggregate scoring system in which a score is allocated to physiological measurements, already recorded in routine practice presentation or when a patient is being monitored in hospital. The score ranges from 0 (best) to 23 (worst). At each visit, only patients with a value at both baseline and the respective visit are included. A negative change from baseline in NEWS2 score is a favorable outcome.
Time frame: Baseline, Days 3, 5, 8, 11, 15, and 29
Change From Baseline in SpO2/FiO2 Ratio
Change from baseline in peripheral oxygen saturation / fraction of inspired oxygen ratio (SpO2/FiO2 ratio). At each visit, only patients with a value at both baseline and the respective visit are included. A positive change from baseline in SpO2/FiO2 ratio is a favorable outcome.
Time frame: Baseline, Day 15, Day 29
Proportion of Patients With no Oxygen Therapy
Proportion of patients with no oxygen therapy (defined as oxygen saturation ≥ 94% on room air) at Days 15 and 29. Analyses are cumulative, thus analysis on each day includes all events till that day. Patients with missing data at Day 15 and/or Day 29 are excluded from the analysis.
Time frame: Day 15, Day 29
Participants took part in 61 investigative sites in 12 countries.
| Milestone | Ruxolitinib 5 mg | Placebo |
|---|---|---|
| Started | 287 | 145 |
| Safety set | 281 | 143 |
| Completed | 269 | 139 |
| Not completed | 18 | 6 |
| Withdrew: Death | 9 | 3 |
| Withdrew: Patient decision | 6 | 3 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Protocol deviation | 1 | 0 |
Efficacy is measured by a composite endpoint of proportion of patients who die, develop respiratory failure \[require mechanical ventilation\], or require intensive care unit \[ICU\] care for the treatment of COVID-19. Analyses are cumulative, thus analysis on Day 29 includes all events till that day. Patients who developed respiratory failure and/or required ICU at randomization are excluded from the analysis.
| Participants | Ruxolitinib 5 mg | Placebo |
|---|---|---|
| Proportion of Patients Who Die, Develop Respiratory Failure [Require Mechanical Ventilation] or Require Intensive Care Unit (ICU) Care | 34 | 17 |
Clinical status is measured with the 9-point ordinal scale. The scoring is: * Uninfected patients have a score 0 (no clinical or virological evidence of infection). * Ambulatory patients (not in hospital or in hospital and ready for discharge) can have a score 1 (no limitation of activities) or 2 (limitation of activities). * Hospitalized patients with mild disease can have score 3 (no oxygen therapy defined as peripheral oxygen saturation (SpO2) ≥ 94% on room air) or 4 (oxygen by mask or nasal prongs). * Hospitalized patients with severe disease can have score 5 (non-invasive ventilation or high-flow oxygen), 6 (intubation and mechanical ventilation) or 7 (ventilation + additional organ support - pressors, RRT (renal replacement therapy), ECMO (extracorporeal membrane oxygenation)). * Patients who die have a score 8.
| score on scale | Ruxolitinib 5 mg | Placebo |
|---|---|---|
| Baseline | 3.7 ± 0.56 | 3.7 ± 0.53 |
| Day 15 | 1.8 ± 1.54 | 1.8 ± 1.41 |
| Day 29 | 1.1 ± 1.61 | 1.0 ± 1.41 |
Percentage of patients with at least two points improvement in clinical status on the 9-point ordinal scale. The baseline value of clinical status is defined as the last assessment prior to first dose of double-blind treatment. Patients with missing data at Day 15 and/or Day 29 are treated as non-responders.
| Participants | Ruxolitinib 5 mg | Placebo |
|---|---|---|
| Day 15 | 206 | 108 |
| Day 29 | 252 | 129 |
Percentage of patients with at least one point improvement in clinical status on the 9-point ordinal scale. The baseline value of clinical status is defined as the last assessment prior to first dose of double-blind treatment. Patients with missing data at Day 15 and/or Day 29 are treated as non-responders.
| Participants | Ruxolitinib 5 mg | Placebo |
|---|---|---|
| Day 15 | 250 | 128 |
| Day 29 | 261 | 136 |
Percentage of patients with at least one point deterioration in clinical status on the 9-point ordinal scale. The baseline value of clinical status is defined as the last assessment prior to first dose of double-blind treatment. Patients with missing data at Day 15 and/or Day 29 are treated as non-responders.
| Participants | Ruxolitinib 5 mg | Placebo |
|---|---|---|
| Day 15 | 16 | 9 |
| Day 29 | 14 | 5 |
Time to improvement in clinical status from baseline category to one less severe category of the 9-point ordinal scale. The baseline value of clinical status is defined as the last assessment prior to first dose of double-blind treatment. Median time to improvement is estimated by Kaplan-Meier method, with dead patients being censored at the maximum follow-up time in the study. Patients who did not achieve improvement and did not die are censored at their last clinical status assessment date.
| days | Ruxolitinib 5 mg | Placebo |
|---|---|---|
| Time to Improvement in Clinical Status | 9.0 (8.0 to 10.0) | 9.0 (8.0 to 12.0) |
Mean change from baseline in the 9-point ordinal scale. The baseline value of clinical status is defined as the last assessment prior to first dose of double-blind treatment. Patients with missing data at Day 15 and/or Day 29 are excluded from the analysis. A negative change from baseline in the clinical status is a favorable outcome.
| score on scale | Ruxolitinib 5 mg | Placebo |
|---|---|---|
| Day 15 | -1.96 ± 0.084 | -1.93 ± 0.118 |
| Day 29 | -2.61 ± 0.090 | -2.69 ± 0.126 |
Mortality rate is determined as the proportion of participants who died by study Day 15 and Day 29
| Participants | Ruxolitinib 5 mg | Placebo |
|---|---|---|
| Day 15 | 6 | 2 |
| Day 29 | 9 | 3 |
Proportion of patients requiring mechanical ventilation. Analyses are cumulative, thus analysis on Day 29 includes all events till that day. Patients who required mechanical ventilation at randomization are excluded from the analysis.
| Participants | Ruxolitinib 5 mg | Placebo |
|---|---|---|
| Proportion of Patients Requiring Mechanical Ventilation | 22 | 10 |
Duration of hospitalization is defined as time to hospital discharge. Median time to hospital discharge is estimated by Kaplan-Meier method, with dead patients being censored at the maximum follow-up time in the study. Patients who were not discharged and did not die are censored at their last assessment date.
| days | Ruxolitinib 5 mg | Placebo |
|---|---|---|
| Duration of Hospitalization | 9.0 (8.0 to 10.0) | 9.0 (8.0 to 12.0) |
The time to hospital discharge or to a National Early Warning Score 2 (NEWS2) of ≤2 and maintained for 24 hours whichever comes first. The NEWS2 is based on a simple aggregate scoring system in which a score is allocated to physiological measurements, already recorded in routine practice presentation or when a patient is being monitored in hospital. The score ranges from 0 (best) to 23 (worst). Median time is estimated by Kaplan-Meier method, with dead patients being censored at the maximum follow-up time in the study.
| days | Ruxolitinib 5 mg | Placebo |
|---|---|---|
| Time to Hospital Discharge or to a NEWS2 Score of ≤2 | 4.0 (3.0 to 4.0) | 4.0 (3.0 to 5.0) |
The National Early Warning Score 2 (NEWS2) is based on a simple aggregate scoring system in which a score is allocated to physiological measurements, already recorded in routine practice presentation or when a patient is being monitored in hospital. The score ranges from 0 (best) to 23 (worst). At each visit, only patients with a value at both baseline and the respective visit are included. A negative change from baseline in NEWS2 score is a favorable outcome.
| score on scale | Ruxolitinib 5 mg | Placebo |
|---|---|---|
| Day 3 | -0.7 ± 1.91 | -0.6 ± 2.13 |
| Day 5 | -1.0 ± 2.02 | -0.8 ± 2.19 |
| Day 8 | -1.3 ± 2.25 | -1.3 ± 2.60 |
| Day 11 | -1.1 ± 2.70 | -1.3 ± 2.74 |
| Day 15 | -1.9 ± 2.34 | -2.2 ± 2.35 |
| Day 29 | -2.3 ± 2.37 | -2.5 ± 2.17 |
Change from baseline in peripheral oxygen saturation / fraction of inspired oxygen ratio (SpO2/FiO2 ratio). At each visit, only patients with a value at both baseline and the respective visit are included. A positive change from baseline in SpO2/FiO2 ratio is a favorable outcome.
| no units | Ruxolitinib 5 mg | Placebo |
|---|---|---|
| Day 15 | 90.110 ± 104.4783 | 106.766 ± 100.9778 |
| Day 29 | 105.553 ± 98.2452 | 109.710 ± 95.4279 |
Proportion of patients with no oxygen therapy (defined as oxygen saturation ≥ 94% on room air) at Days 15 and 29. Analyses are cumulative, thus analysis on each day includes all events till that day. Patients with missing data at Day 15 and/or Day 29 are excluded from the analysis.
| Participants | Ruxolitinib 5 mg | Placebo |
|---|---|---|
| Day 15 | 255 | 133 |
| Day 29 | 262 | 136 |
Deaths in the safety population were evaluated in all participants who received at least one dose of double-blind treatment. Total deaths were evaluated in all participants randomized.
| participants | Ruxolitinib 5 mg | Placebo |
|---|---|---|
| Deaths in the safety population | 9 | 3 |
| Total deaths | 9 | 3 |
Collected over From first dose of double-blind treatment and up to the last study visit (Day 29).. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ruxolitinib 5 mg | 9/281 (3.2%) | 31/281 (11%) | 113/281 (40.2%) |
| Placebo | 3/143 (2.1%) | 15/143 (10.5%) | 62/143 (43.4%) |
| Event | Ruxolitinib 5 mg | Placebo |
|---|---|---|
| COVID-19Infections and infestations | 8/281 | 3/143 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 4/281 | 4/143 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 4/281 | 1/143 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 2/281 | 2/143 |
| PneumoniaInfections and infestations | 3/281 | 0/143 |
| Cardiopulmonary failureCardiac disorders | 0/281 | 1/143 |
| VertigoEar and labyrinth disorders | 0/281 | 1/143 |
| Multiple organ dysfunction syndromeGeneral disorders | 1/281 | 1/143 |
| Escherichia bacteraemiaInfections and infestations | 0/281 | 1/143 |
| Urinary tract infectionInfections and infestations | 0/281 | 1/143 |
| Event | Ruxolitinib 5 mg | Placebo |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 21/281 | 12/143 |
| HeadacheNervous system disorders | 23/281 | 11/143 |
| NauseaGastrointestinal disorders | 6/281 | 11/143 |
| Alanine aminotransferase increasedInvestigations | 17/281 | 6/143 |
| ConstipationGastrointestinal disorders | 9/281 | 7/143 |
| HypokalaemiaMetabolism and nutrition disorders | 8/281 | 7/143 |
| CoughRespiratory, thoracic and mediastinal disorders | 12/281 | 3/143 |
| HyperkalaemiaMetabolism and nutrition disorders | 6/281 | 6/143 |
| FatigueGeneral disorders | 10/281 | 2/143 |
| HyperglycaemiaMetabolism and nutrition disorders | 4/281 | 5/143 |
| Age, Continuous(years) | Ruxolitinib 5 mg | Placebo | Total |
|---|---|---|---|
| Mean | 56.4 ± 13.7 | 56.9 ± 12.5 | 56.5 ± 13.3 |
| Sex: Female, Male(Participants) | Ruxolitinib 5 mg | Placebo | Total |
|---|---|---|---|
| Female | 125 | 72 | 197 |
| Male | 162 | 73 | 235 |
| Race/Ethnicity, Customized(Participants) | Ruxolitinib 5 mg | Placebo | Total |
|---|---|---|---|
| White | 242 | 109 | 351 |
| American Indian Or Alaska Native | 26 | 13 | 39 |
| Black Or African American | 6 | 9 | 15 |
| Asian | 5 | 5 | 10 |
| Multiple | 3 | 2 | 5 |
| Unknown | 5 | 7 | 12 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from May 2020 to primary completion in Oct 2020, 5 months.
Results were first posted in Jun 2021, 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ruxolitinib